223 related articles for article (PubMed ID: 27872727)
1. Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.
Martinelli S; Cuneo A; Formigaro L; Cavallari M; Lista E; Quaglia FM; Ciccone M; Bardi A; Volta E; Tammiso E; Saccenti E; Sofritti O; Daghia G; Negrini M; Dabusti M; Tomasi P; Moretti S; Cavazzini F; Rigolin GM
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016047. PubMed ID: 27872727
[TBL] [Abstract][Full Text] [Related]
2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
3. [Survival analysis of 118 chronic lymphocytic leukemia patients with abnormal TP53 gene in the era of traditional immunochemotherapy].
Li XT; Zhu HY; Wang L; Xia Y; Liang JH; Wu JZ; Wu W; Cao L; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):378-383. PubMed ID: 31207701
[No Abstract] [Full Text] [Related]
4. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
5. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients.
Ricca I; Rocci A; Drandi D; Francese R; Compagno M; Lobetti Bodoni C; De Marco F; Astolfi M; Monitillo L; Vallet S; Calvi R; Ficara F; Omedè P; Rosato R; Gallamini A; Marinone C; Bergui L; Boccadoro M; Tarella C; Ladetto M
Leukemia; 2007 Apr; 21(4):697-705. PubMed ID: 17301820
[TBL] [Abstract][Full Text] [Related]
6. Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages.
Suárez-Cabrera A; Fiallo-Suárez DV; Stuckey R; Uroz-de la Iglesia ML; Florido Y; Lemes-Castellano A; Perera-Álvarez MÁ; Luzardo-Henríquez H; de la Nuez H; Fernández-Caldas P; de la Iglesia S; Gómez-Casares MT; Bilbao-Sieyro C
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892513
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
8. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
9. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
10. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Molica S; Giannarelli D; Mirabelli R; Levato L; Russo A; Linardi M; Gentile M; Morabito F
Eur J Haematol; 2016 Jan; 96(1):72-7. PubMed ID: 25819739
[TBL] [Abstract][Full Text] [Related]
11. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
Rani L; Gogia A; Singh V; Kumar L; Sharma A; Kaur G; Gupta R
Ann Hematol; 2019 Feb; 98(2):437-443. PubMed ID: 30338367
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
16. An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
Cohen JA; Bomben R; Pozzo F; Tissino E; Härzschel A; Hartmann TN; Zucchetto A; Gattei V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272636
[TBL] [Abstract][Full Text] [Related]
17. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
18. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
Van Dyke DL; Werner L; Rassenti LZ; Neuberg D; Ghia E; Heerema NA; Dal Cin P; Dell Aquila M; Sreekantaiah C; Greaves AW; Kipps TJ; Kay NE
Br J Haematol; 2016 Apr; 173(1):105-13. PubMed ID: 26848054
[TBL] [Abstract][Full Text] [Related]
19. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).
Zenz T; Fröhling S; Mertens D; Döhner H; Stilgenbauer S
Best Pract Res Clin Haematol; 2010 Mar; 23(1):71-84. PubMed ID: 20620972
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Factors for Chronic Lymphocytic Leukemia.
Chen C; Puvvada S
Curr Hematol Malig Rep; 2016 Feb; 11(1):37-42. PubMed ID: 26748932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
